Richard Barry, President and CEO and Director of Filana Therapeutics, Inc., filed a Form 4 on November 18, 2026, disclosing an open market purchase of common stock on November 16, 2026.
Key Highlights
- Shares acquired: 440,206 shares of Filana Therapeutics common stock were purchased on November 16, 2026.
- Weighted average price: The reported per-share price was $0.47, representing a weighted average across multiple open market transactions.
- Price range: Individual transactions occurred at prices ranging from $0.45 to $0.48 per share, according to the filing.
- Post-transaction ownership: Following the purchase, the reporting person beneficially owned 1,778,170 shares, held indirectly by trust.
- Roles: Richard Barry serves as both a Director and President and CEO of the issuer.
- Signing authority: The form was signed by Eric J. Schoen by Power of Attorney on November 18, 2026.
Richard Barry's Open Market Purchase of Filana Therapeutics Common Stock
According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 18, 2026, Richard Barry, who holds the roles of Director and President and CEO at Filana Therapeutics, Inc. (NASDAQ:FLNA), acquired 440,206 shares of the company's common stock on November 16, 2026. The transaction was coded "P," indicating an open market purchase.
The filing disclosed that the reported per-share price of $0.47 is a weighted average. The shares were purchased across multiple open market transactions at prices ranging from $0.45 to $0.48 per share. The filing noted that the reporting person "undertakes to provide to Filana, any security holder of Filana or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote."
Following the reported transaction, Richard Barry's total beneficial ownership stands at 1,778,170 shares, held indirectly through a trust. The filing was submitted by Eric J. Schoen acting by Power of Attorney. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
Richard Barry, President and CEO and Director of Filana Therapeutics, Inc., disclosed the open market purchase of 440,206 common shares at a weighted average price of $0.47 per share on November 16, 2026, bringing his indirect beneficial ownership to 1,778,170 shares held by trust.





Please wait processing your request...